GIP; GLP-1 and glucagon receptor tri-agonist
Retatrutide 8 mg subcutaneous once weekly
RETA_SC_8MG_QW
Effects across outcomes
Bayesian random effects estimate against the comparator of each analysis (usually placebo), posterior median and 95% credible interval. Green: clearly better; red: clearly worse.
| Condition | Outcome | Window | Versus | Effect (95% CrI) | SUCRA |
|---|---|---|---|---|---|
| Type 2 diabetes (adults) | Serious adverse events | longest follow-up | Placebo | HR 1.19 (0.25 to 4.90) | 0.43 |
| Type 2 diabetes (adults) | Nausea | longest follow-up | Placebo | HR 6.63 (2.87 to 16.29) | 0.18 |
| Type 2 diabetes (adults) | Vomiting | longest follow-up | Placebo | HR 3.56 (1.05 to 12.10) | 0.41 |
| Type 2 diabetes (adults) | Constipation | longest follow-up | Placebo | HR 2.74 (0.73 to 10.11) | 0.32 |
| Overweight or obesity without diabetes (adults) | Percent body weight change | weeks 20 to 40 (target week 26) | Placebo | MD -15.47 (-20.43 to -7.77) | 0.94 |
| Overweight or obesity without diabetes (adults) | Percent body weight change | weeks 40 to 104 (target week 68) | Placebo | MD -19.69 (-25.53 to -8.93) | 0.78 |
| Overweight or obesity without diabetes (adults) | Serious adverse events | longest follow-up | Placebo | HR 0.97 (0.19 to 4.90) | 0.55 |
| Overweight or obesity without diabetes (adults) | Nausea | longest follow-up | Placebo | HR 3.73 (1.71 to 8.67) | 0.47 |
| Overweight or obesity without diabetes (adults) | Vomiting | longest follow-up | Placebo | HR 6.05 (1.66 to 28.57) | 0.37 |
| Overweight or obesity without diabetes (adults) | Diarrhea | longest follow-up | Placebo | HR 1.80 (0.71 to 4.85) | 0.52 |
| Overweight or obesity without diabetes (adults) | Constipation | longest follow-up | Placebo | HR 2.95 (0.79 to 12.98) | 0.36 |